Welcome to our dedicated page for Immunocore Holdings Plc news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings Plc stock.
Immunocore Holdings plc (Nasdaq: IMCR) is a commercial-stage biotechnology company focused on T cell receptor (TCR) bispecific immunotherapies for cancer, infectious diseases and autoimmune diseases. News about Immunocore frequently centers on the commercial performance and clinical development of its lead product, KIMMTRAK, which is approved for HLA‑A*02:01‑positive adult patients with unresectable or metastatic uveal melanoma in multiple regions, and on its broader melanoma franchise.
Investors following IMCR news can expect regular updates on Phase 3 oncology trials, including the TEBE‑AM registrational trial of tebentafusp in second‑line or later advanced cutaneous melanoma, the ATOM adjuvant uveal melanoma trial, and the PRISM‑MEL‑301 trial evaluating brenetafusp plus nivolumab in first‑line advanced cutaneous melanoma. Company press releases also describe progress in Phase 1/2 studies of PRAME‑targeting ImmTAC candidates across ovarian cancer, non‑small cell lung cancer and other solid tumors.
Beyond oncology, Immunocore issues news on its ImmTAV infectious disease programs, such as IMC‑M113V for people living with HIV and IMC‑I109V for chronic hepatitis B infection, including early clinical data on safety, pharmacodynamic effects and viral antigen reductions. Updates on ImmTAAI candidates for autoimmune conditions, including type 1 diabetes and inflammatory dermatological diseases, are also part of the company’s communications.
This IMCR news page aggregates company press releases, conference participation announcements and SEC‑related disclosures, giving readers a single view of developments in KIMMTRAK commercialization, pipeline milestones, trial readouts and strategic priorities across oncology, infectious disease and autoimmune pipelines.
Immunocore (Nasdaq: IMCR) reported 3Q 2025 results and a business update on November 6, 2025. KIMMTRAK net product sales were $103.7M in the quarter (+29% YoY) and $295.5M year-to-date. Cash, cash equivalents and marketable securities were $892.4M as of September 30, 2025. The company is advancing multiple registrational trials: Phase 3 TEBE-AM (enrollment on track to complete 1H 2026) and Phase 3 PRISM-MEL-301 (brenetafusp 160 mcg selected by IDMC). R&D and SG&A increased QoQ, and GAAP net loss was ($0.2M) in 3Q 2025. Key pipeline areas include oncology (PRAME, IMC-R117C), infectious disease (HIV, HBV), and autoimmune programs.
Resolution Therapeutics has strengthened its leadership team with two key appointments: Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. The appointments follow the successful dosing of the first patient in the company's Phase I/II EMERALD study.
Lucy Singah brings over 20 years of corporate and strategic finance experience from companies including Echopoint Medical, GSK, and EY. Daniel Kennedy, with more than 20 years of business development experience, joins from Immunocore (NASDAQ: IMCR) and previously led deals at Achillion Pharmaceuticals, including its $930 million acquisition by Alexion.
The company will host an R&D Webinar on September 17, 2025, featuring clinical hepatologists to discuss its regenerative macrophage therapy (RMT) platform for inflammatory and fibrotic diseases.
Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company will participate in the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Morgan Stanley Global Healthcare Conference (Sept 10).
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their flagship product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Immunocore (NASDAQ:IMCR) reported strong Q2 2025 financial results, with KIMMTRAK net revenues reaching $98.0 million, representing a 30% year-over-year growth. The company achieved significant market expansion with KIMMTRAK now approved in 39 countries and launched in 28 countries globally.
Key highlights include 15% growth in US sales and 71% growth in Europe and international regions. The company maintains a strong financial position with $883 million in cash and equivalents. R&D expenses increased to $69.0 million, reflecting investments in autoimmune programs and Phase 3 trials.
Clinical progress remains on track with the Phase 3 TEBE-AM trial expected to complete enrollment in 1H 2026, and dose selection for PRISM-MEL-301 Phase 3 trial anticipated in 2H 2025. The company reported a reduced net loss of $10.3 million compared to $11.6 million in the same period last year.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company, will release its second quarter 2025 financial results on Thursday, August 7, 2025, before US markets open. The company will host a conference call and webcast at 8:00 a.m. EDT to discuss results and provide business updates.
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their lead product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Immunocore (NASDAQ: IMCR) has presented initial data from the multiple ascending dose (MAD) portion of its Phase 1/2 STRIVE trial for IMC-M113V, a functional HIV cure candidate. The study included 16 HIV-positive participants across three dose cohorts (60 mcg, 120 mcg, and 300 mcg).
Key findings show that IMC-M113V was well-tolerated with no serious adverse events. The 300 mcg cohort showed promising results, with 2 out of 5 patients demonstrating viral control. Notably, these patients maintained viral loads around 200 c/mL at week 8, significantly better than the historical rate of 5%.
The trial revealed dose-dependent viral control after antiretroviral treatment interruption, with some patients showing reduced CD4+ T cell-associated HIV Gag RNA, indicating a reduction in active virus reservoir. Two patients remained off antiretroviral treatment for the entire 12-week interruption period, with one patient showing viral reduction to 50 c/mL at week 12 - an outcome typically seen in <1% of cases.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced its participation in three major investor conferences in March 2025.
The company will be present at:
- The TD Cowen 45th Annual Healthcare Conference with a presentation on Tuesday, March 4, 2025, at 3:10 p.m. EST
- The Barclays 27th Annual Global Healthcare Conference for a fireside chat on Tuesday, March 11, 2025, at 3:00 p.m. EST
- The Jefferies Biotech on the Beach Summit for one-on-one and small group meetings on Wednesday, March 12, 2025
Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website. Replay options will be available for a time after the events.
Immunocore (NASDAQ: IMCR) reported Q4 2024 financial results with KIMMTRAK net sales of $84.1M and full-year sales of $310.0M. The company achieved 11 consecutive quarters of revenue growth and expanded to 14 new territories.
Q4 net loss was $23.8M ($0.47 per share) compared to $19.7M in Q4 2023. Full-year 2024 net loss was $51.1M ($1.02 per share) versus $55.3M in 2023. R&D expenses increased to $222.2M from $163.5M in 2023.
Key developments include:
- KIMMTRAK now approved in 39 countries and launched in 24
- First patient randomized in Phase 3 PRISM-MEL-301 trial
- Initiated Phase 1/2 trial of IMC-R117C for colorectal cancers
- Strong cash position of $820.4M as of December 31, 2024
- Repaid $50M Pharmakon loan in November 2024